Clinical evaluation of an oral progestin contraceptive, R-2323, 5mg, administered at weekly intervals.
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced; D001706:Biopsy; D004341:Drug Evaluation; D004717:Endometrium / Q000473:pathology; D004967:Estrogens / Q000097:blood; D005260:Female; D005306:Fertilization / Q000187:drug effects; D006067:Gonanes / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D006914:Hydroxysteroids / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D007664:Ketosteroids / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D008598:Menstruation / Q000187:drug effects; D008599:Menstruation Disturbances / Q000139:chemically induced; D008796:Metrorrhagia / Q000139:chemically induced; D011247:Pregnancy; D011372:Progestins / Q000009:adverse effects / Q000494:pharmacology*
D004967:Estrogens; D006067:Gonanes; D006914:Hydroxysteroids; D007664:Ketosteroids; D011372:Progestins